This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_MARGINAL_ZONE_LYMPHOMA_EXALLC for full statistics.
Marginal zone B-cell lymphoma
C3_MARGINAL_ZONE_LYMPHOMA
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
286 |
4. Check minimum number of eventsNone |
286 |
5. Include endpointsNone |
286 |
6. Filter based on genotype QC (FinnGen only) |
286 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Marginal zone B-cell lymphoma
based on the number of shared cases.
Similar with more cases:
- Marginal zone B-cell lymphoma, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
- Any event in cancer register
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 286 | 142 | 144 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.06 |
| Median age at first event (years) | 65.42 | 64.05 | 66.77 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 265
- Matched controls
- 2651
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
5891.1
281.5
220
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
35.4
80.0
105
48
XW000
NOMESCO Finland
Bone marrow biopsy
29.7
75.9
105
57
JN4BD
NOMESCO Finland
Extensive body CT
11.3
55.8
120
180
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
36.1
52.8
68
25
9699/3-C16.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of stomach, NOS
+∞
37.4
35
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
24.9
36.1
51
25
JN6AD
NOMESCO Finland
CT of torso and neck
45.0
34.6
42
11
WF002
NOMESCO Finland
Radical radiotherapy
11.1
34.4
69
81
9699/3-C77.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of lymph node, NOS
+∞
34.1
32
*
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
59.1
31.2
36
7
C85.7
ICD-10 Finland
Other specified types of non-Hodgkin lymphoma
312.4
28.3
28
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
34.4
28.0
36
12
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
31.7
27.5
36
13
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
11.3
26.8
52
56
A03FA01
ATC
metoclopramide; systemic, rectal
4.8
26.5
110
342
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
34.0
25.7
33
11
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
74.7
24.3
27
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
40.4
23.5
29
8
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.9
23.3
137
570
EP1AE
NOMESCO Finland
Neck ultrasound examination
8.4
23.1
53
76
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
49.8
22.8
27
6
C83.89
ICD-10 Finland
Other types of diffuse non-Hodgkin's lymphoma
65.6
21.2
24
*
JN4AD
NOMESCO Finland
Body CT examination
5.8
20.3
62
132
9699/3-C42.1
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of bone marrow
+∞
20.0
19
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
9.3
19.4
41
51
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
6.8
19.0
50
87
9699/3-C77.8
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of lymph nodes of multiple regions
+∞
19.0
18
*
1XC02
NOMESCO Finland
NA
47.7
18.5
22
5
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
56.7
18.2
21
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
16.1
18.1
29
20
M04AA01
ATC
allopurinol; systemic
4.3
17.8
74
218
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
8.4
17.5
39
53
L03AA02
ATC
filgrastim; parenteral
11.6
17.2
32
31
9699/3-C34.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of lung, NOS
+∞
16.8
16
*
XX3DW
NOMESCO Finland
Time consuming IT work
4.8
16.6
60
153
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
35.8
16.0
20
6
9699/3-C69.6
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of orbit, NOS
+∞
15.8
15
*
C83.8
ICD-10 Finland
Other non-follicular lymphoma
169.4
15.6
16
*
9699/3-C07.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of parotid gland
+∞
14.7
14
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
16.6
14.7
23
15
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
14.2
114
543
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
32.0
14.1
18
6
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.8
13.7
40
79
CAA30
NOMESCO Finland
Biopsy of orbit
+∞
13.7
13
*
L03AA13
ATC
pegfilgrastim; parenteral
7.0
13.2
33
53
PJA10
NOMESCO Finland
Exploration of lymph nodes
14.0
13.2
22
17
ZX120
NOMESCO Finland
Intravenous
4.1
13.0
54
156
A04AA02
ATC
granisetron; systemic, transdermal
5.5
12.9
39
81
C83.39
ICD-10 Finland
Diffuse non-Hodgkin's large cell lymphoma UNS
73.4
12.7
14
*
A04AA01
ATC
ondansetron; systemic, rectal
5.2
12.7
40
87
WW500
NOMESCO Finland
Blood transfusion
7.2
12.4
30
46
C82.9
ICD-10 Finland
Follicular lymphoma, unspecified
39.5
12.3
15
*
CFA20
NOMESCO Finland
Biopsy of conjunctiva
39.5
12.3
15
*
C83.00
ICD-10 Finland
Lymphocytic lymphoma
49.0
12.0
14
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
15.6
12.0
19
13
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
14.5
11.6
19
14
9699/3-C69.0
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of conjunctiva
+∞
11.5
11
*
R50.9
ICD-10 Finland
Fever, unspecified
3.6
11.5
56
184
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.6
10.9
52
168
H02AB06
ATC
prednisolone; systemic
2.4
10.9
149
918
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
13.7
10.8
18
14
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
10.6
58
207
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
34.0
10.4
13
*
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
10.7
10.2
19
19
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
10.1
51
172
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
57.1
9.7
11
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
31.2
9.5
12
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.3
9.4
142
891
D31.6
ICD-10 Finland
Benign neoplasm: Orbit, unspecified
+∞
9.4
9
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
10.1
9.4
18
19
CBA10
NOMESCO Finland
Biopsy of eyelid
25.0
9.0
12
5
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
13.1
9.0
15
12
A02BC02
ATC
pantoprazole; systemic
2.3
9.0
195
1439
9680/3-C77.9
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of lymph node, NOS
51.7
8.7
10
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.2
8.7
119
707
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
4.6
8.5
29
69
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
9.9
8.4
16
17
9699/3-C44.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of skin, NOS
+∞
8.4
8
*
9699/3-C08.0
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of submandibular gland
+∞
8.4
8
*
C88.4
ICD-10 Finland
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lyphoma]
+∞
8.4
8
*
9699/3-C80.9
ICD-O-3
Marginal zone B-cell lymphoma, NOS, of unknown primary site
+∞
8.4
8
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.3
8.4
90
476
D11.0
ICD-10 Finland
Benign neoplasm: Parotid gland
7.6
8.1
18
25
TGE00
NOMESCO Finland
Needle biopsy of mediastinum
46.3
7.8
9
*
ZX112
NOMESCO Finland
Subcutaneous
7.1
7.7
18
27
WZC30
NOMESCO Finland
Teaching
2.9
7.5
49
195
1AA09
NOMESCO Finland
NA
82.2
7.5
8
*
D37.00
ICD-10 Finland
Aryepiglottic fold marginal zone
82.2
7.5
8
*
C83.01
ICD-10 Finland
Lymphoplasmacytic lymphoma
+∞
7.3
7
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
16.3
7.3
11
7
WF004
NOMESCO Finland
Palliative radiotherapy
6.9
7.2
17
26
WF049
NOMESCO Finland
Radiotherapy of metastasis
5.0
7.2
22
47
H02AB02
ATC
dexamethasone; systemic
3.0
7.0
43
163
ZX090
NOMESCO Finland
Other technic of radiotherapy
5.1
7.0
21
44
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.7
6.8
28
81
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
23.2
6.7
9
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
7.7
6.5
14
19
C82.1
ICD-10 Finland
Follicular lymphoma grade II
14.8
6.4
10
7
R22.1
ICD-10 Finland
Localized swelling, mass and lump, neck
4.5
6.3
21
50
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.8
6.3
40
158
L01AA02
ATC
chlorambucil; oral
27.4
6.3
8
*
ZX108
NOMESCO Finland
Inhalation
27.4
6.3
8
*
C82.01
ICD-10 Finland
Follicular nodular lymphoma, grade I
27.4
6.3
8
*
EL4AT
NOMESCO Finland
Salivary gland cytology with ultrasound guidance
27.4
6.3
8
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.0
6.3
35
126
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
6.3
6.1
15
25
H02AB07
ATC
prednisone; oral
2.4
6.1
52
240
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
71
21
44.64
115.05
1.5
1.2
—
—
—
0
0
37
16
26.41
51.90
2.5
2.6
17.8
14.5
%
—
13
8
33
17
21.81
42.97
4.9
2.3
587.7
919.9
e6/l
—
18
7
33
17
21.81
42.97
2.5
2.6
—
—
—
0
0
232
1124
6.64
41.12
11.2
5.3
56.9
57.4
%
0.27
225
1051
250
1390
7.34
34.94
20.6
9.1
3.5
4.1
e9/l
7.63
244
1218
217
1083
5.16
34.49
7.4
4.5
35.6
35.1
g/l
0.59
209
1009
84
210
5.25
32.96
2.2
2.7
67.4
67.1
g/l
0.12
78
187
26
18
15.79
29.15
5.4
3.8
28.3
36.3
%
—
12
6
54
105
6.11
27.68
2.0
1.9
—
—
—
0
0
54
105
6.11
27.68
2.0
1.9
6.8
7.5
g/l
1.54
44
81
53
105
5.97
26.60
2.0
1.9
4.0
3.8
g/l
0.08
42
76
25
0
+∞
26.46
1.1
0.0
—
—
—
0
0
51
98
6.12
26.41
2.0
1.9
3.0
3.1
g/l
0.13
43
78
221
1258
4.33
25.95
9.2
6.4
1.2
1.2
mmol/l
0.81
188
1054
48
91
6.14
25.16
1.9
2.3
2.1
0.8
g/l
0.91
42
79
35
54
7.25
22.29
4.7
6.2
416.0
153.6
iu/ml
—
6
8
30
41
8.06
21.19
1.3
1.4
—
—
—
0
0
28
36
8.51
20.78
1.3
1.4
95.7
98.1
u/ml
—
6
7
159
840
3.01
18.71
5.1
3.2
2.4
2.4
mmol/l
0.17
149
728
26
36
7.84
18.11
2.2
2.0
33.9
33.0
pg
0.42
26
36
35
67
5.81
17.99
2.0
1.7
—
—
—
0
0
109
483
3.03
17.39
4.1
2.9
2.5
2.5
mmol/l
0.35
109
425
28
47
6.50
16.38
4.9
3.1
1.2
1.0
%
0.11
22
40
19
7
28.92
14.47
2.3
1.6
—
—
—
0
0
30
63
5.20
13.89
1.5
1.3
—
—
—
0
0
18
7
27.29
13.54
5.6
1.4
—
—
—
0
0
20
31
6.86
12.54
5.7
2.2
46.2
54.5
%
0.60
12
23
22
38
6.19
12.46
1.0
1.2
—
—
—
0
0
21
35
6.40
12.31
1.0
1.1
331.9
324.7
u/ml
0.03
14
22
34
91
4.11
11.68
1.8
2.7
—
—
—
0
0
105
564
2.36
10.45
3.3
2.4
—
—
—
0
0
11
10
11.40
10.22
2.9
2.0
—
—
—
0
0
11
10
11.40
10.22
2.9
2.0
—
—
—
0
0
11
10
11.40
10.22
2.9
2.0
—
—
—
0
0
11
10
11.40
10.22
2.9
2.0
—
—
—
0
0
34
104
3.58
9.65
3.5
2.0
1.6
1.5
g/l
0.22
29
90
21
45
4.96
9.46
2.2
2.0
—
—
—
0
0
165
1105
2.17
9.25
6.2
4.0
—
—
—
0
0
16
28
5.99
8.90
3.0
1.9
—
—
—
0
0
10
10
10.33
8.69
3.0
1.9
—
—
—
0
0
24
62
4.13
8.61
2.1
1.9
—
—
—
0
0
24
62
4.13
8.61
2.4
1.9
—
—
—
0
0
15
27
5.81
8.11
2.6
1.9
—
—
—
0
0
103
605
2.10
7.83
2.6
2.1
3.2
3.2
mg/l
0.03
95
524
70
353
2.30
7.78
2.5
2.3
25.5
23.1
%
0.42
61
304
75
398
2.20
7.34
2.7
2.2
13.9
13.1
umol/l
0.27
70
364
71
369
2.23
7.31
2.5
2.2
2.2
2.3
g/l
0.48
66
336
85
478
2.11
7.15
1.7
1.7
1257.7
1213.7
nmol/l
0.16
66
356
76
415
2.13
6.87
2.7
2.0
—
—
—
0
0
11
17
6.69
6.82
1.9
1.2
—
—
—
0
0
22
65
3.58
6.56
1.4
1.3
2.7
2.3
u/ml
—
8
12
22
66
3.53
6.42
1.4
1.3
2.1
8.1
u/ml
—
10
16
24
78
3.27
6.20
2.0
2.2
—
—
—
0
0
137
946
1.86
6.17
3.6
2.6
290.0
140.4
ug/l
1.91
128
860
11
19
5.98
6.15
1.0
1.0
—
—
—
0
0
71
398
2.04
5.91
2.6
1.8
29.7
29.6
s
0.08
66
386
10
9
11.46
5.84
3.0
2.0
—
—
—
0
0
10
9
11.46
5.84
3.0
2.0
—
—
—
0
0
12
24
5.18
5.79
2.7
1.8
—
—
—
0
0
12
24
5.18
5.79
2.8
1.8
—
—
—
0
0
12
24
5.18
5.79
2.7
1.8
—
—
—
0
0
48
237
2.23
5.51
2.1
2.2
0.2
0.2
g/l
0.26
42
221
136
963
1.79
5.44
2.9
2.1
80.7
78.8
nmol/l
0.29
130
829
39
181
2.34
5.17
2.7
1.6
—
—
—
0
0
10
19
5.42
5.07
2.4
3.9
—
—
—
0
0
11
23
4.93
5.05
2.6
2.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
77
3.01
5.05
2.3
2.6
0.3
0.5
u/ml
1.08
14
41
55
297
2.05
5.02
2.3
1.9
—
—
—
0
0
18
56
3.36
4.98
1.1
1.2
—
—
—
0
0
139
1009
1.73
4.96
2.3
2.0
92.1
94.7
pmol/l
0.26
81
513
53
288
2.03
4.75
2.0
4.0
2.5
48.2
ug/l
1.04
38
244
16
48
3.47
4.68
1.1
1.9
—
—
—
0
0
14
40
3.63
4.39
5.6
2.2
3.0
4.7
e9/l
2.66
14
40
68
417
1.83
4.24
2.8
3.1
2.6
2.2
e6/l
0.16
41
234
53
301
1.93
4.18
2.3
2.0
—
—
—
0
0
77
496
1.76
4.06
3.6
3.8
121.8
228.0
ng/l
0.50
61
405
19
70
2.84
4.01
1.2
1.4
—
—
—
0
0
14
43
3.37
3.96
7.0
2.9
56.2
55.8
%
0.02
14
43
19
71
2.80
3.91
1.9
1.3
—
—
—
0
0
260
2337
2.24
3.88
32.4
15.3
19.8
24.6
mg/l
1.23
242
1862
21
84
2.62
3.81
2.4
2.4
127.6
294.4
ug/l
1.20
21
77
42
229
1.98
3.71
4.6
3.5
2.1
1.9
mmol/l
0.11
35
187
7
9
7.94
3.58
1.0
1.0
—
—
—
0
0
12
36
3.44
3.52
1.0
2.1
—
—
—
0
0
11
31
3.65
3.52
1.1
2.0
—
—
—
0
0
41
227
1.94
3.47
5.7
7.5
1.2
1.4
mmol/l
0.40
41
216
12
37
3.34
3.38
1.2
1.2
—
—
—
0
0
67
440
1.68
3.24
2.9
2.9
0.8
1.1
e6/l
0.54
39
252
98
708
1.58
3.24
3.8
3.2
0.3
0.6
e6/l
1.31
72
526
10
28
3.66
3.22
1.4
2.1
—
—
—
0
0
21
92
2.38
3.18
3.4
1.9
—
—
—
0
0
40
229
1.87
3.07
4.8
3.5
5.9
5.8
kpa
0.20
40
223
12
40
3.09
3.01
1.0
2.0
—
—
—
0
0
5
5
10.14
2.99
1.2
1.2
—
—
—
0
0
5
5
10.14
2.99
3.4
2.8
—
—
iu/ml
—
0
0
119
913
1.52
2.95
4.2
3.2
—
—
—
0
0
30
160
1.98
2.84
1.8
1.4
—
—
—
0
0
10
31
3.31
2.80
1.2
1.0
—
—
—
0
0
5
6
8.45
2.76
1.0
1.0
—
—
—
0
0
5
6
8.45
2.76
1.0
1.0
—
—
—
0
0
15
60
2.58
2.75
1.3
1.2
—
—
—
0
0
11
38
2.97
2.61
1.1
1.9
—
—
—
0
0
246
2240
1.70
2.53
28.5
14.7
76.9
76.8
ml/min/173m2
0.03
233
1831
102
783
1.47
2.43
3.1
2.4
58.8
54.8
u/l
0.45
93
715
22
111
2.06
2.43
5.2
3.9
24.3
24.2
mmol/l
0.04
22
100
6
12
5.08
2.41
1.0
1.3
—
—
—
0
0
5
8
6.34
2.38
1.2
1.0
—
—
—
0
0
10
35
2.92
2.33
1.1
1.2
—
—
—
0
0
73
528
1.51
2.32
1.7
1.7
1.4
1.3
mg/l
0.09
56
418
11
41
2.75
2.30
1.4
1.8
—
—
—
0
0
6
13
4.69
2.28
2.2
1.4
—
—
—
0
0
6
13
4.69
2.28
2.2
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
9
5.63
2.22
1.2
1.0
—
—
—
0
0
5
9
5.63
2.22
1.2
1.6
—
—
—
0
0
8
24
3.40
2.19
1.3
1.0
—
—
—
0
0
83
623
1.47
2.19
1.7
1.6
20.1
21.3
nmol/l
0.26
74
508
9
30
3.06
2.16
1.2
2.9
2.1
4.1
nmol/l
—
9
30
6
14
4.35
2.16
2.2
1.4
—
—
—
0
0
6
14
4.35
2.16
2.2
1.4
—
—
—
0
0
8
25
3.26
2.11
1.3
1.0
—
—
—
0
0
11
45
2.50
1.95
1.7
1.4
—
—
—
0
0
11
45
2.50
1.95
1.7
1.4
—
—
—
0
0
6
16
3.81
1.94
2.2
1.8
—
—
—
0
0
6
16
3.81
1.94
1.2
1.1
—
—
—
0
0
6
16
3.81
1.94
2.2
1.8
—
—
—
0
0
28
167
1.75
1.92
1.9
1.7
—
—
—
0
0
9
34
2.70
1.88
4.2
1.5
—
—
—
0
0
9
36
2.55
1.75
4.2
1.4
—
—
—
0
0
9
36
2.55
1.75
4.2
1.4
—
—
—
0
0
9
36
2.55
1.75
4.2
1.4
—
—
—
0
0
9
36
2.55
1.75
4.2
1.4
—
—
—
0
0
6
19
3.20
1.67
1.3
1.3
166.5
272.0
u/l
—
6
19
6
19
3.20
1.67
1.2
1.0
—
—
—
0
0
6
19
3.20
1.67
1.2
2.1
—
—
—
0
0
39
265
1.55
1.65
3.8
3.4
—
—
—
0
0
5
14
3.61
1.62
1.0
1.0
—
—
—
0
0
5
14
3.61
1.62
1.2
3.3
58.2
99.7
nmol/l
—
5
14
23
138
1.72
1.57
7.4
10.7
24.8
24.5
mmol/l
0.30
23
129
16
86
1.91
1.53
2.8
1.7
—
—
—
0
0
121
1020
1.32
1.52
3.2
3.9
22.7
40.3
ng/l
2.26
90
769
9
37
2.48
1.49
4.2
1.4
—
—
—
0
0
223
2055
1.39
1.49
31.5
16.6
37.4
39.4
%
1.70
146
1396
206
2223
0.74
1.47
6.1
6.2
39.7
40.4
mmol/mol
0.51
187
2045
168
1489
1.31
1.44
3.7
3.2
51.0
51.8
u/l
0.05
157
1369
193
1744
1.33
1.44
3.9
3.7
14.8
14.9
pmol/l
0.28
180
1532
60
458
1.39
1.42
1.3
1.2
7.2
1.0
u/ml
0.63
11
119
24
151
1.64
1.40
6.8
3.1
1.2
2.0
mmol/l
0.59
18
121
6
23
2.64
1.37
2.7
3.2
25.7
84.2
u/ml
—
6
23
91
754
1.30
1.26
2.2
2.0
203.2
197.4
u/l
0.02
83
699
50
380
1.38
1.22
1.3
1.3
34.1
33.9
iu/ml
0.00
18
122
132
1152
1.27
1.21
3.4
3.8
0.0
0.0
estimate
0.00
30
209
141
1241
1.27
1.20
2.5
2.5
—
—
—
0
0
12
64
1.91
1.20
1.8
1.5
—
—
—
0
0
8
38
2.14
1.19
1.1
1.6
—
—
—
0
0
13
72
1.84
1.17
3.3
2.3
1.6
1.6
mg/l
0.07
13
63
95
814
1.25
0.98
2.5
3.3
1685.1
1329.9
ng/l
0.30
83
697
9
51
1.79
0.95
1.1
1.3
—
—
—
0
0
39
298
1.36
0.94
1.2
1.3
—
—
—
0
0
10
55
1.85
0.93
3.0
1.4
46188.0
24381.7
e6/l
—
10
36
131
1171
1.22
0.90
3.5
3.8
0.0
0.0
estimate
0.00
31
196
6
29
2.09
0.90
1.0
1.2
—
—
—
0
0
46
365
1.31
0.87
1.2
1.3
6.4
10.4
u/ml
0.34
17
127
11
64
1.75
0.87
1.0
1.4
—
—
—
0
0
6
31
1.96
0.85
1.3
1.6
28.5
16.9
ug/l
—
6
31
11
65
1.72
0.83
1.5
1.2
—
—
—
0
0
62
515
1.26
0.83
1.5
1.8
566.9
446.5
pmol/l
0.77
51
421
11
66
1.69
0.80
1.5
1.2
—
—
—
0
0
6
33
1.84
0.79
1.2
1.5
—
—
—
0
0
21
151
1.42
0.73
1.3
1.3
—
36.8
—
0
10
5
25
2.02
0.73
1.0
1.4
—
—
—
0
0
16
109
1.50
0.72
1.2
1.1
183.3
148.2
iu/ml
—
7
39
9
59
1.54
0.69
4.4
1.4
—
—
—
0
0
127
1158
1.17
0.65
5.0
5.2
0.0
0.0
estimate
0.00
30
210
5
29
1.74
0.64
1.0
1.1
—
—
—
0
0
56
654
0.82
0.63
1.8
1.6
1.4
1.4
mmol/l
0.00
47
540
10
63
1.61
0.62
1.9
1.2
—
—
—
0
0
38
309
1.26
0.62
7.7
7.7
—
—
—
0
0
222
2308
0.83
0.62
4.4
4.6
1.4
1.5
mmol/l
1.84
198
2083
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
5
30
1.68
0.61
1.0
1.1
—
—
—
0
0
8
53
1.52
0.59
1.0
1.7
—
—
—
0
0
241
2331
1.22
0.55
5.2
4.9
6.0
6.0
mmol/l
0.51
217
2102
231
2382
0.84
0.50
5.0
5.3
2.5
2.7
mmol/l
1.34
206
2149
222
2138
1.17
0.50
5.0
4.5
1.9
2.6
mu/l
0.58
203
1904
28
340
0.80
0.47
4.6
4.7
28.9
31.7
%
0.87
17
216
5
31
1.62
0.43
1.4
1.1
—
—
—
0
0
226
2327
0.86
0.43
4.4
4.7
4.4
4.6
mmol/l
1.14
202
2116
0
16
0.00
0.41
0.0
1.3
—
1.7
—
0
9
7
102
0.68
0.40
1.1
1.0
—
—
—
0
0
42
366
1.17
0.38
21.6
23.7
1.1
1.3
inr
—
7
41
6
46
1.31
0.33
2.5
1.3
—
—
—
0
0
6
47
1.28
0.32
1.3
1.4
—
—
—
0
0
7
52
1.35
0.31
1.0
1.1
—
—
—
0
0
12
97
1.25
0.23
1.4
1.6
—
—
—
0
0
5
41
1.22
0.22
1.2
1.3
—
—
—
0
0
12
98
1.23
0.21
1.7
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
39.0
—
0
6
0
11
0.00
0.21
0.0
1.2
—
106.7
—
0
6
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
7.3
—
0
6
13
151
0.85
0.16
1.7
1.8
—
—
—
0
0
65
616
1.07
0.16
3.6
4.1
0.0
0.0
estimate
0.00
31
197
9
88
1.02
0.07
1.4
1.5
—
—
—
0
0
90
880
1.03
0.07
3.7
4.0
—
—
—
0
0
56
543
1.04
0.06
2.9
3.0
0.7
0.7
ug/l
0.04
36
365
222
2237
0.97
0.06
4.0
4.2
1.4
1.3
mmol/l
1.48
196
2006
93
943
0.98
0.03
4.8
5.1
2.5
2.4
ug/l
0.06
84
832
20
192
1.04
0.02
2.2
3.0
52.4
61.1
ml/min/173m2
—
8
82
74
746
0.99
0.00
4.4
4.5
20.5
20.8
%
0.06
35
363
26
263
0.99
0.00
1.4
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
9.5
—
0
9
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
5
49
1.02
0.00
1.0
3.7
13.2
31.4
u/ml
—
5
49
0
6
0.00
0.00
0.0
2.0
—
1.2
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_MARGINAL_ZONE_LYMPHOMA – Marginal zone B-cell lymphoma
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).